SCHEDULE: Frazier Life Sciences Amends DISC Medicine Stake Disclosure
Ownership Disclosure Amendment
Frazier Life Sciences and its affiliates filed an amended Schedule 13G, clarifying their beneficial ownership in DISC Medicine, Inc. and correcting prior attribution.
Summary
- Frazier Life Sciences Public Fund, L.P. and its related entities beneficially own 1,026,489 shares of DISC Medicine, Inc. common stock, representing 3.0% of the class.
- Frazier Life Sciences Public Overage Fund, L.P. and its related entities beneficially own 300,643 shares, representing 0.9% of the class.
- Frazier Life Sciences X, L.P. and its related entities, including James N. Topper and Patrick J. Heron, beneficially own 63,218 shares, representing 0.2% of the class.
- Frazier Life Sciences XI, L.P. and its related entities beneficially own 264,484 shares, representing 0.8% of the class.
- The aggregate beneficial ownership for the Frazier Life Sciences group totals 1,654,834 shares, representing approximately 4.78% of the outstanding common stock.
- The filing clarifies that members of the investment committees for certain funds are not attributed beneficial ownership of the securities held directly by those funds, correcting previous overstatements.
- All percentages are calculated based on 34,634,295 shares of Common Stock outstanding on April 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2025.
Sentiment
Score: 5
Explanation: This is a factual ownership disclosure filing (Schedule 13G/A) and does not contain information that inherently conveys positive or negative sentiment regarding the issuer's performance or prospects. It primarily clarifies beneficial ownership attribution.
Future Outlook
NA
Industry Context
DISC Medicine, Inc. operates in the biotechnology sector. Frazier Life Sciences is a prominent venture capital firm focused on life sciences investments. This filing represents a standard ownership disclosure for institutional investors in the biotech industry.
Stakeholder Impact
- Primarily impacts shareholders by providing updated clarity on significant beneficial ownership stakes and their attribution.
Key Dates
| Date | Description |
|---|---|
| 2025-04-30 | Date of Common Stock outstanding calculation for percentage determination. |
| 2025-05-07 | Date of Issuer's Quarterly Report on Form 10-Q filing, which stated the number of outstanding shares. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-14 | Date of signing of the Schedule 13G Amendment. |
Keywords
DISC Medicine, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Biotechnology, SEC Filing, Institutional Investor, Ownership Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.